{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Deaths that occur during the protocol specified AE reporting period (Section 6.1.6) that', 'are more likely related to disease progression will therefore be considered as an expected', 'SAE and will not be subject to expedited reporting. These events should be recorded on', 'the AE eCRF as described in Section 6.1.1.3. After the AE reporting period, deaths', 'attributed to progression of disease under study should not be recorded on the AE eCRF.', 'Section 6.1.5 Adverse Event Collection Period', 'First paragraph, first sentence previously read:', 'All adverse events reported from the time of blinded investigational product', 'administration until 70 days following discontinuation of blinded investigational product', 'administration will be collected, whether solicited or spontaneously reported by the', 'subject.', 'Has been changed to read:', 'All adverse events reported from the time of blinded investigational product', 'administration until 70 days following the last dose of blinded investigational product will', 'be collected, whether solicited or spontaneously reported by the subject.', 'Section 6.1.6 Adverse Event Reporting', '\"Primary Therapeutic Area Medical Director:\" previously read:', 'Therapeutic Area Medical Director', 'AbbVie', '200 Sidney Street', 'Cambridge, MA 02139', 'Telephone Contact Information:', 'Office:', 'Mobile:', 'Email:', '178']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Senior Medical Director', 'AbbVie', '1 North Waukegan Road', 'North Chicago, IL 60064', 'USA', 'Telephone Contact Information:', 'Office:', 'Mobile:', 'Email:', 'Section 6.1.6 Adverse Event Reporting', 'Fifth paragraph previously read:', 'The sponsor will be responsible for Suspected Unexpected Serious Adverse Reactions', '(SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with', 'Directive 2001/20/EC. The reference document used for SUSAR reporting in the EU', \"countries will be the most current version of the Investigator's Brochure14 and the most\", 'current version of the Summary of Product Characteristics (SmPC).', 'Has been changed to read:', 'AbbVie will be responsible for Suspected Unexpected Serious Adverse Reactions', '(SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with', 'global and local guidelines and Appendix A of the Investigator Brochure will serve as the', 'Reference Safety Information (RSI). The RSI in effect at the start of a DSUR reporting', 'period serves as the RSI during the reporting period. For follow-up reports, the RSI in', \"place at the time of occurrence of the 'suspected' Serious Adverse Reaction will be used to\", 'assess expectedness.', '179']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 6.1.8.1 Management of Serosal Effusions/Serositis', 'First paragraph, first sentence previously read:', 'Serosal effusions (pleural or pericardial, or ascites) have been observed with', 'rovalpituzumab tesirine and have the potential to be life-threatening (e.g., pericardial', 'tamponade).', 'Has been changed to read:', 'Serosal effusions (pleural or pericardial, or ascites) have been observed with', 'rovalpituzumab tesirine and have the potential to be life-threatening (e.g., cardiac', 'tamponade).', 'Section 6.1.8.1 Management of Serosal Effusions/Serositis', 'First paragraph', 'Add: new fifth and sixth sentence', 'Effusion events were reported during treatment and may occur up to several months after', 'last Rova-T dose. As a result, subjects should be advised of signs and symptoms of fluid', 'retention and contact treating physician if they arise during this time.', 'Section 6.1.8.2 Management of Skin Reactions', 'Add: new second paragraph', 'Photosensitivity reactions may occur hours to days after sun exposure. Patients should be', 'advised to avoid direct and indirect sun exposure as much as possible from Cycle 1 Day 1', 'until 30 days after the final dose. When sun exposure is unavoidable, patients should', 'wear protective clothing and sunglasses, and use a broad-spectrum sunscreen and lip balm', '(SPF 30 or greater). Thirty-one to ninety days after last dose of Rova-T/placebo, the', 'patient may resume outdoor activities with appropriate sun protection including broad', 'brimmed hat, protective clothing and sunscreen SPF 30 or higher. Subjects with a grade 3', 'photosensitivity reaction should dose reduce Rova-T/placebo to 0.2 mg/kg after the first', 'occurrence and following a second grade 3 photosensitivity reaction, reduce Rova-', '180']\n\n###\n\n", "completion": "END"}